JP Morgan Chase’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $35.4K | Buy |
5,181
+68
| +1% | +$528 | ﹤0.01% | 6336 |
|
|
2025
Q4 | $36.1K | Buy |
5,113
+1,419
| +38% | +$11K | ﹤0.01% | 6342 |
|
|
2025
Q3 | $27.6K | Sell |
3,694
-2,767
| -43% | -$21K | ﹤0.01% | 6405 |
|
|
2025
Q2 | $47.5K | Buy |
6,461
+2,961
| +85% | +$25.8K | ﹤0.01% | 5946 |
|
|
2025
Q1 | $27K | Buy |
3,500
+231
| +7% | +$2.53K | ﹤0.01% | 6065 |
|
|
2024
Q4 | $39.6K | Buy |
3,269
+237
| +8% | +$3.03K | ﹤0.01% | 6098 |
|
|
2024
Q3 | $38K | Buy |
3,032
+57
| +2% | +$735 | ﹤0.01% | 6070 |
|
|
2024
Q2 | $35.5K | Sell |
2,975
-17,053
| -85% | -$234K | ﹤0.01% | 5985 |
|
|
2024
Q1 | $350K | Buy |
20,028
+19,736
| +6,759% | +$356K | ﹤0.01% | 5019 |
|
|
2023
Q4 | $7.5K | Sell |
292
-178
| -38% | -$2.52K | ﹤0.01% | 6481 |
|
|
2023
Q3 | $3.4K | Buy |
470
+467
| +15,567% | +$3.13K | ﹤0.01% | 6439 |
|
|
2023
Q2 | $18 | Hold |
3
| – | – | ﹤0.01% | 6794 |
|
|
2023
Q1 | $0 | Sell |
3
-4
| -57% | -$15 | ﹤0.01% | 6922 |
|
|
2022
Q4 | $0 | Hold |
7
| – | – | ﹤0.01% | 6734 |
|
|
2022
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 6614 |
|
|
2022
Q2 | $0 | Sell |
7
-404
| -98% | -$2.69K | ﹤0.01% | 6638 |
|
|
2022
Q1 | $2K | Buy |
411
+404
| +5,771% | +$2K | ﹤0.01% | 6421 |
|
|
2021
Q4 | $0 | Sell |
7
-4,141
| -100% | -$70.8K | ﹤0.01% | 6770 |
|
|
2021
Q3 | $128K | Sell |
4,148
-7,185
| -63% | -$236K | ﹤0.01% | 5445 |
|
|
2021
Q2 | $368K | Sell |
11,333
-5,596
| -33% | -$192K | ﹤0.01% | 4889 |
|
|
2021
Q1 | $640K | Buy |
16,929
+5,757
| +52% | +$263K | ﹤0.01% | 4527 |
|
|
2020
Q4 | $529K | Buy |
11,172
+4,233
| +61% | +$183K | ﹤0.01% | 4332 |
|
|
2020
Q3 | $227K | Buy |
6,939
+3,811
| +122% | +$149K | ﹤0.01% | 4302 |
|
|
2020
Q2 | $137K | Buy |
+3,128
| New | +$147K | ﹤0.01% | 4430 |
|
|
2020
Q1 | – | Sell |
-1,992
| Closed | -$102K | – | 5457 |
|
|
2019
Q4 | $102K | Sell |
1,992
-19,421
| -91% | -$814K | ﹤0.01% | 4889 |
|
|
2019
Q3 | $789K | Sell |
21,413
-8,152
| -28% | -$439K | ﹤0.01% | 3963 |
|
|
2019
Q2 | $1.7M | Sell |
29,565
-895
| -3% | -$55.9K | ﹤0.01% | 3491 |
|
|
2019
Q1 | $1.85M | Buy |
30,460
+11,599
| +61% | +$745K | ﹤0.01% | 3382 |
|
|
2018
Q4 | $1.12M | Buy |
18,861
+10,035
| +114% | +$740K | ﹤0.01% | 3678 |
|
|
2018
Q3 | $714K | Buy |
8,826
+8,412
| +2,032% | +$667K | ﹤0.01% | 4102 |
|
|
2018
Q2 | $36K | Buy |
+414
| New | +$72.6K | ﹤0.01% | 5181 |
|
|
2014
Q4 | – | Sell |
-20
| Closed | -$39K | – | 4270 |
|
|
2014
Q3 | $39K | Buy |
+20
| New | +$49.4K | ﹤0.01% | 4129 |
|
|
2013
Q4 | – | Sell |
-30
| Closed | -$128K | – | 4148 |
|
|
2013
Q3 | $128K | Buy |
30
+3
| +11% | +$12.1K | ﹤0.01% | 4139 |
|
|
2013
Q2 | $92K | Buy |
+27
| New | +$103K | ﹤0.01% | 4170 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
JP Morgan Chase's GYRE Position: Q1 2026 in Review
JP Morgan Chase increased its Gyre Therapeutics (GYRE) stake by 1.3% in Q1 2026, buying an estimated $528 and bringing the position to 5,181 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6336.
JP Morgan Chase first reported a position in GYRE in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.85M in Q1 2019. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- JP Morgan Chase held 5,181 shares of Gyre Therapeutics worth $35.4K as of Q1 2026.
- JP Morgan Chase bought 68 Gyre Therapeutics shares in Q1 2026, an estimated $528.
- Gyre Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6336 holding.
- JP Morgan Chase first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 34 quarters since.
- JP Morgan Chase's Gyre Therapeutics position peaked at $1.85M in Q1 2019.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.